Astonea Labs
Astonea Labs (ASTONEALAB) share price was ₹323.00 at the 19 Oct 2026 close; market capitalisation ₹340 Cr; sector Healthcare. The share price rose 101.9% over the year to 19 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue was ₹81 Cr and net profit was ₹3 Cr. Promoters held 72.44% of Astonea Labs in Sep 2026, up 0.14 percentage points from Mar 2026. Its Tapetide Score is 47/100 (Average) as of 28 Oct 2026.
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 19 Oct 2026, 15:30 IST · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,766.50 | 35.04 | 4,23,843 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,635.00 | 87.45 | 2,55,779 Cr | 15.26 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,598.40 | 72.19 | 1,74,908 Cr | 9.52 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,184.70 | 107.94 | 1,18,042 Cr | 22.27 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,180.50 | 26.27 | 1,17,755 Cr | 4.34 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,341.00 | 34.73 | 1,11,931 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.50 | 32.83 | 1,10,717 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Astonea Labs (this company) | — | — | 340 Cr | 5.94 | 0.00% | 7.90% | 11.34% | — | — |
| Median 8 companies | ₹1,766.50 | 35.04 | 1,17,899 Cr | 5.51 | 0.47% | 12.98% | 16.41% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 81/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Weaknesses
3- Stock is trading at 5.96 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 41.3 days to 74.2 days
Technical Indicators
Oscillators
Neutral
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 10% · Mar 2026
Quarterly Results
| Particulars | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 47 | 66 | 81 |
| Expenses | 41 | 61 | 73 |
| Operating Profit | 7 | 5 | 8 |
| OPM % | 14% | 8% | 10% |
| Other Income | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 3 |
| PBT | 3 | 2 | 4 |
| Tax % | 24% | 20% | 20% |
| Net Profit | 2 | 1 | 3 |
| EPS (₹) | 2.76 | 1.35 | 2.95 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 30 | 67 | 80 | 98 | 148 |
| Expenses | 24 | 60 | 68 | 82 | 134 |
| Operating Profit | 6 | 7 | 12 | 15 | 14 |
| OPM % | 19% | 11% | 15% | 16% | 9% |
| Other Income | 0 | 0 | 0 | 0 | 1 |
| Interest | 2 | 2 | 3 | 4 | 3 |
| Depreciation | 4 | 4 | 4 | 5 | 5 |
| PBT | 1 | 1 | 5 | 7 | 6 |
| Tax % | 57% | 39% | 24% | 24% | 20% |
| Net Profit | 0 | 1 | 4 | 5 | 5 |
| EPS (₹) | 0.33 | 0.88 | 5.36 | 6.93 | 4.3 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 8 | 8 | 11 |
| Reserves | 3 | 4 | 4 | 11 | 47 |
| Borrowings | 30 | 36 | 42 | 53 | 43 |
| Other Liabilities | 16 | 20 | 26 | 32 | 46 |
| Total Liabilities | 53 | 64 | 81 | 103 | 146 |
| Fixed Assets | 21 | 21 | 22 | 26 | 31 |
| CWIP | 0 | 0 | 2 | 4 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 |
| Other Assets | 32 | 44 | 57 | 73 | 101 |
| Total Assets | 53 | 64 | 81 | 103 | 146 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | -5 | -1 | 8 | 9 | -14 |
| Investing | -3 | -3 | -8 | -11 | -20 |
| Financing | 8 | 4 | 0 | 2 | 34 |
| Net Cash Flow | 0 | 0 | -1 | 0 | 0 |
| Free Cash Flow | -8 | -4 | 0 | -2 | -28 |
| CFO/EBITDA | -75 | -9 | 71 | 70 | -88 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 235 | 104 | 116 | 142 | 129 |
| Inventory Days | 136 | 121 | 161 | 161 | 125 |
| Days Payable | 273 | 128 | 149 | 144 | 150 |
| Cash Conversion Cycle | 98 | 97 | 128 | 159 | 103 |
| Working Capital Days | 98 | 33 | 28 | 22 | 74 |
| ROCE % | — | 8% | 17% | 17% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Astonea Labs insights
59 extracted metrics + investor summaries across FY22–FY26.
Documents
Frequently Asked Questions about Astonea Labs
What does Astonea Labs Ltd do?
Where is Astonea Labs Ltd (ASTONEALAB) listed?
Which sector does Astonea Labs Ltd belong to?
What is the market capitalisation of Astonea Labs Ltd?
What is the 52-week high and low of Astonea Labs Ltd?
What is the Return on Equity (ROE) of Astonea Labs Ltd?
Company Information
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544409.md for Astonea Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.